EU Medicines Safety Updates

The European Medicines Agency (EMA), through its Pharmacovigilance Risk Assessment Committee (PRAC) and other committees, is actively safeguarding EU citizens by continuously monitoring and updating medicine safety information. Recent actions include new safety guidance for widely used contraceptives, clarifying risks associated with valproate for male patients, and mandating enhanced liver monitoring for Ontozry. This ongoing vigilance ensures that prescribed medications remain safe and effective, with information for healthcare professionals and patients consistently updated EU-wide.

Beyond safety reviews, the EU is expanding treatment options and bolstering its pharmaceutical resilience. The EMA's Committee for Medicinal Products for Human Use (CHMP) has recommended a total of 15 new medicines for approval in recent months, covering diverse therapeutic areas and offering new treatments like Redemplo for familial chylomicronaemia syndrome. This proactive approach to bringing innovative treatments to market is complemented by the recently agreed Critical Medicines Act, which aims to secure a stable supply of essential medicines, mitigating shortages and strengthening the EU's pharmaceutical market against future disruptions. These parallel efforts underscore the EU's commitment to both immediate patient safety and long-term access to critical treatments.